We performed an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir plus ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naïve or -experienced patients with HCV genotype 3 infection.